A study of the neuropathy associated with transthyretin amyloidosis (ATTR) in the UK

被引:49
作者
Carr, A. S. [1 ]
Pelayo-Negro, A. L. [1 ,2 ]
Evans, M. R. B. [1 ]
Laura, M. [1 ]
Blake, J. [1 ,3 ]
Stancanelli, C. [4 ]
Iodice, V. [4 ]
Wechalekar, A. D. [5 ]
Whelan, C. J. [5 ]
Gillmore, J. D. [5 ]
Hawkins, P. N. [5 ]
Reilly, M. M. [1 ]
机构
[1] UCL Inst Neurol, MRC Ctr Neuromuscular Dis, Box 108,Queen Sq, London WC1N 3BG, England
[2] Univ Hosp Marques De Valdecilla, Dept Neurol, Santander, Spain
[3] Norfolk & Norwich Univ Hosp, Dept Clin Neurophysiol, Norwich, Norfolk, England
[4] Natl Hosp Neurol & Neurosurg, Auton Unit, Box 108,Queen Sq, London WC1N 3BG, England
[5] UCL, Sch Med, Natl Amyloidosis Ctr, Royal Free Campus, London, England
基金
英国医学研究理事会;
关键词
POLYNEUROPATHY; NORTH; EPIDEMIOLOGY; TAFAMIDIS; VARIANT; ONSET;
D O I
10.1136/jnnp-2015-310907
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Hereditary transthyretin amyloidosis (ATTR) is usually characterised by a progressive peripheral and autonomic neuropathy often with associated cardiac failure and is due to dominantly inherited transthyretin mutations causing accelerated amyloid deposition. The UK population is unique in that the majority of patients have the T60A missense mutation in ATTR where tyrosine is replaced by adenine at position 60. This has been traced to a single founder mutation from north-west Ireland. The neuropathy phenotype is less well described than the cardiac manifestations in this group. Methods We present the findings from an observational cohort study of patients with ATTR attending the National Hospital Inherited Neuropathy Clinic between 2009 and 2013. Detailed clinical neurological and electrophysiological data were collected on all patients alongside correlating autonomic and cardiac assessments. Follow-up data were available on a subset. Results Forty-four patients with genetically confirmed ATTR were assessed; 37 were symptomatic; mean age at onset=62 years, range=38-75 years; 75.7% male. T60A was the most common mutation (17/37), followed by V30M (5/37). A severe, rapidly progressive, predominantly length dependent axonal sensorimotor neuropathy was the predominant phenotype. T60A patients were distinguished by earlier and more frequent association with carpal tunnel syndrome; a predominance of negative sensory symptoms at onset; significant vibration deficits; and a non-length dependent progression of motor deficit. Progression of the neuropathy was observed over a relatively short follow-up period (2 years) in 20 patients with evidence of clinically measurable annual change in Medical Research Council (MRC) sum score (-1.5 points per year) and Charcot Marie Tooth Neuropathy Score (CMTNS: 2.7 points per year), and a congruent trend in the electrophysiological measures used. Conclusion The description of the ATTR neuropathy phenotype, especially in the T60A patients, should aid early diagnosis as well as contribute to the understanding of its natural history.
引用
收藏
页码:620 / 627
页数:8
相关论文
共 35 条
[1]  
Adams D, BRAIN
[2]   FAP Neuropathy and Emerging Treatments [J].
Adams, David ;
Theaudin, Marie ;
Cauquil, Cecile ;
Algalarrondo, Vincent ;
Slama, Michel .
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2014, 14 (03)
[3]  
ALTROCCHI PH, 1993, NEUROLOGY, V43, P2406
[5]   Genotype, echocardiography, and survival in familial transthyretin amyloidosis [J].
Arruda-Olson, Adelaide M. ;
Zeldenrust, Steven R. ;
Dispenzieri, Angela ;
Gertz, Morie A. ;
Miller, Fletcher A. ;
Bielinski, Suzette J. ;
Klarich, Kyle W. ;
Scott, Christopher G. ;
Grogan, Martha .
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2013, 20 (04) :263-268
[6]   Repurposing Diflunisal for Familial Amyloid Polyneuropathy A Randomized Clinical Trial [J].
Berk, John L. ;
Suhr, Ole B. ;
Obici, Laura ;
Sekijima, Yoshiki ;
Zeldenrust, Steven R. ;
Yamashita, Taro ;
Heneghan, Michael A. ;
Gorevic, Peter D. ;
Litchy, William J. ;
Wiesman, Janice F. ;
Nordh, Erik ;
Corato, Manuel ;
Lozza, Alessandro ;
Cortese, Andrea ;
Robinson-Papp, Jessica ;
Colton, Theodore ;
Rybin, Denis V. ;
Bisbee, Alice B. ;
Ando, Yukio ;
Ikeda, Shu-ichi ;
Seldin, David C. ;
Merlini, Giampaolo ;
Skinner, Martha ;
Kelly, Jeffery W. ;
Dyck, Peter J. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (24) :2658-2667
[7]   A NOVEL VARIANT OF TRANSTHYRETIN, 59(THR)-](LYS), ASSOCIATED WITH AUTOSOMAL-DOMINANT CARDIAC AMYLOIDOSIS IN AN ITALIAN FAMILY [J].
BOOTH, DR ;
TAN, SY ;
HAWKINS, PN ;
PEPYS, MB ;
FRUSTACI, A .
CIRCULATION, 1995, 91 (04) :962-967
[8]  
Burgess R., 2011, NEW PRINCIPLES BEST, V2nd
[9]   Transthyretin V122I amyloidosis with clinical and histological evidence of amyloid neuropathy and myopathy [J].
Carr, A. S. ;
Pelayo-Negro, A. L. ;
Jaunmuktane, Z. ;
Scalco, R. S. ;
Hutt, D. ;
Evans, M. R. B. ;
Heally, E. ;
Brandner, S. ;
Holton, J. ;
Blake, J. ;
Whelan, C. J. ;
Wechalekar, A. D. ;
Gillmore, J. D. ;
Hawkins, P. N. ;
Reilly, M. M. .
NEUROMUSCULAR DISORDERS, 2015, 25 (06) :511-515
[10]   Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy [J].
Coelho, Teresa ;
Maia, Luis F. ;
da Silva, Ana Martins ;
Cruz, Marcia W. ;
Plante-Bordeneuve, Violaine ;
Suhr, Ole B. ;
Conceicao, Isabel ;
Schmidt, Hartmut H. -J. ;
Trigo, Pedro ;
Kelly, Jeffery W. ;
Labaudiniere, Richard ;
Chan, Jason ;
Packman, Jeff ;
Grogan, Donna R. .
JOURNAL OF NEUROLOGY, 2013, 260 (11) :2802-2814